Suven Life Sciences Q1 net up 16.68 pc at Rs 34.74 cr

Suven Life Sciences today reported a 16.68 per cent increase in its net profit at Rs 34.74 crore for the first quarter ended June 30, 2014.

The company had posted a net profit of Rs 29.77 crore in the corresponding quarter last fiscal, Suven Life Sciences said in a filing to BSE.

Net sales during the period under review stood at Rs 141.53 crore as against Rs 108.67 crore, up 30.23 per cent.

During the quarter, revenue from contract research and manufacturing services (CRAMS) stood at Rs 138.95 crore as compared to Rs 106.89 crore in the year-ago period.

On the other hand, income from drug discovery, development and support services stood at Rs 2.58 crore as against Rs 1.78 crore in Q1 last fiscal, the company said.

Suven's major thrust on innovative R&D in drug discovery continues with a spending of Rs 8.9 crore, which is 6.28 per cent of revenue for the quarter ended June 30, 2014, it added.

Shares of Suven Life Sciences were trading at Rs 123.15 per scrip in the morning trade, down 0.28 per cent from the previous close on BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • RBI has been wise to retain policy rates

    The Reserve Bank of India has been wise to retain policy rates in its latest money policy announcement.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Education domain must be autonomous

Few issues in the higher education domain exist despite numerous ...

Rajgopal Nidamboor

Can we modify our emotional bearings?

We are not always a replica of our thoughts, emotions ...

Gautam Gupta

French fashion icon Gaultier’s pret goodbye

With Gaultier gone, the world of international prêt will never ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture